What are the most common side effects of Foundayo?

The label lists nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain and others among reactions reported in at least 5% of patients. The full frequency table is in the label itself, linked below; any percentage quoted on this page is the label's own figure.

Do the side effects mean the price is not the issue?

They meet at titration. Most of these reactions are worst in the weeks after a dose increase, and those are also the weeks when some sellers charge a lower starting price. So the months people are most likely to stop are not the months that show what the drug costs. The maintenance price is on the Foundayo price page.

← Foundayo (orforglipron)

Foundayo (orforglipron) side effects

Foundayo's FDA label lists 13 common reactions, 8 serious warnings and 2 contraindications, plus a boxed warning. All of them are below in the label's own order; any percentage is the label's own figure, and nothing here is a recommendation.

No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price

Last updated 2026-08-13 — the version of the FDA label this page quotes. Read and dated by Alex Seot.

What are the side effects of Foundayo?

The FDA label for Foundayo lists nausea, constipation, diarrhea, vomiting and indigestion among the reactions reported in at least 5% of patients. It carries a boxed warning, the strongest the FDA issues: The label carries the GLP-1 class boxed warning for thyroid C-cell tumors, and says why it applies here: GLP-1 receptor agonists that are pharmacologically active in rats and mice caused thyroid C-cell tumors at clinically relevant exposures. The label's serious warnings include acute pancreatitis; severe gastrointestinal reactions; acute kidney injury from volume depletion; and hypoglycemia. It is contraindicated in 2 cases, among them a personal or family history of medullary thyroid carcinoma, or MEN 2, meaning the label says not to prescribe it at all. Every line above is quoted from FDA prescribing information for FOUNDAYO rather than summarized from a secondary source, because a side-effect list paraphrased twice stops being the label. That label version was published 2026-08-13.

Boxed warning — the strongest warning the FDA issues

The label carries the GLP-1 class boxed warning for thyroid C-cell tumors, and says why it applies here: GLP-1 receptor agonists that are pharmacologically active in rats and mice caused thyroid C-cell tumors at clinically relevant exposures. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents; because it is active at the human GLP-1 receptor, the label says the human relevance of those rodent tumors has not been determined. It is contraindicated outright with a personal or family history of medullary thyroid carcinoma or MEN 2.

Common, and usually manageable

Reactions the label reports in at least 5% of patients.

nausea
constipation
diarrhea
vomiting
indigestion
abdominal pain
headache
bloating
fatigue
burping
reflux
flatulence
hair loss

A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. In the two trials 8% stopped because of side effects, against 3% on placebo, 5% of them because of gastrointestinal ones. Nausea, vomiting and diarrhea were more common during dose escalation and decreased over time. Above 5.5 mg every step is optional, taken on response and tolerability, so the pace is a conversation with the prescriber rather than a reason to quit unannounced.

Serious, and worth knowing before you start

Acute pancreatitis, reported in patients treated with Foundayo, and fatal and non-fatal hemorrhagic or necrotizing pancreatitis with GLP-1 receptor agonists. The label says to stop the drug if it is suspected
Severe gastrointestinal reactions: about 3% on orforglipron against 1% on placebo. Not recommended in severe gastroparesis
Acute kidney injury from volume depletion, in some cases needing dialysis, reported mostly in people who became dehydrated through nausea, vomiting or diarrhea
Hypoglycemia: plasma glucose under 54 mg/dL in 2% on orforglipron against 0.2% on placebo in the type 2 diabetes trial, and 7% among those also taking a sulfonylurea
Hypersensitivity reactions including anaphylaxis and angioedema, reported with GLP-1 receptor agonists and a reason to stop the drug
Diabetic retinopathy complications in people with type 2 diabetes, when glucose control improves rapidly. The drug has not been studied in retinopathy or macular edema needing acute treatment
Acute gallbladder disease: cholelithiasis in 1% against 0.7% on placebo and acute cholecystitis in 0.4% against 0.3%
Pulmonary aspiration during general anesthesia or deep sedation: the drug delays gastric emptying, and stomach contents have been found despite normal preoperative fasting. Tell any surgeon or anesthesiologist you are taking it

Who cannot take it

A personal or family history of medullary thyroid carcinoma, or MEN 2
Known serious hypersensitivity to orforglipron

Each of these, on its own

What the label says, why it happens, how it tracks the dose schedule and the point at which it stops being ordinary.

What it costs Dosage schedule

Everything on Foundayo

Questions

What are the most common side effects of Foundayo?: The label lists nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain and others among reactions reported in at least 5% of patients. The full frequency table is in the label itself, linked below; any percentage quoted on this page is the label's own figure.
Who should not take it?: The label contraindicates it in these cases: A personal or family history of medullary thyroid carcinoma, or MEN 2; Known serious hypersensitivity to orforglipron.
Do the side effects mean the price is not the issue?: They meet at titration. Most of these reactions are worst in the weeks after a dose increase, and those are also the weeks when some sellers charge a lower starting price. So the months people are most likely to stop are not the months that show what the drug costs. The maintenance price is on the Foundayo price page.

Source: FDA prescribing information for FOUNDAYO, the version published 2026-08-13. Information only, not medical advice: a side effect you are having is a conversation with your prescriber, not with a comparison site.